Quality of Life Measurement in Treatment Naïve Patients With HCV Genotype 1 Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) (HEMATITE)
Study description
This is an observational, prospective, open-label, single-arm, multicenter, real-life study designed to observe the impact of paritaprevir/ritonavir/ombitasvir with dasabuvir regimen (Viekirax®/Exviera®, 3D regimen) on total daytime physical activity and fatigue in participants with Hepatitis C Virus (HCV) genotype 1 (GT1).
Pathology
Hepatitis C Virus HCV
Study type
Post-marketing observation study
Status
Terminated
Study start date
2017
Study completion date
2018
Funder Type
Industry funded study
Investigator
Dr. med. Lorenzo MAGENTA
Recruitment
Completed